Search Results
Your search for ,WHo matches 20933 pages
Showing 14051 - 14100Higher Complete Pathologic Regression Rate With Neoadjuvant Docetaxel- vs Epirubicin-Based Triplets in Gastric/Gastroesophageal Junction Cancer
In the phase II portion of a German phase II/III trial (FLOT4) reported in The Lancet Oncology, Al-Batran et al found that preoperative docetaxel-based vs anthracycline-based triplet therapy produced a higher complete histopathologic regression rate in patients with resectable gastric or...
Gut Microbes Linked to Immunotherapy Response in Patients With Melanoma
Patients with malignant melanoma are more likely to respond to immunotherapy treatment if they have greater diversity in their gut bacteria, according to new research presented by Wargo et al at the National Cancer Research Institute's (NCRI) Cancer Conference in Liverpool, United Kingdom....
Fulvestrant Superior to Anastrozole as Initial Therapy in Advanced Breast Cancer
Fulvestrant (Faslodex) was superior to anastrozole as initial treatment of hormone receptor–positive, endocrine therapy–naive, advanced breast cancer, significantly reducing the risk of disease progression or death, according to the results of the phase III FALCON study presented at the 2016...
Expert Point of View: Jean-Charles Soria, MD, PhD
A number of lung cancer specialists were anxious to comment on the positive findings of KEYNOTE-024 and were equally perplexed about the negative results of CheckMate-026. All agreed that the overall survival benefit makes pembrolizumab (Keytruda) a game-changer for the first-line treatment of...
Pembrolizumab, but Not Nivolumab, Improves Outcomes in Front-Line Setting for PD-L1–Positive Advanced NSCLC
Checkpoint inhibitors have revolutionized the treatment of advanced non–small cell lung cancer (NSCLC), but evidence of their benefit was restricted to the second-line setting. However, early-phase trials with both pembrolizumab (Keytruda) and nivolumab (Opdivo) demonstrated favorable results in...
Mammography Outcomes Improve When Physicians Compare Prior Screenings
The recall rate of screening mammography is reduced when radiologists compare with more than one prior mammogram, according to a recent study by Hayward et al in American Journal of Roentgenology. “Our findings suggest that radiologists who make comparisons with more than one prior...
Multiple Genetic Mutational Signatures Associated With Smoking
Scientists have measured the genetic damage caused by smoking in different organs of the body and identified several different mechanisms by which tobacco smoking causes mutations in DNA. Researchers at the Wellcome Trust Sanger Institute, the Los Alamos National Laboratory, and their collaborators ...
7 Substances Added to HHS 14th Report on Carcinogens
The release of the U.S. Department of Health and Human Services (HHS) 14th Report on Carcinogens on November 3, 2016, included 7 newly reviewed substances, bringing the cumulative total to 248 listings. The chemical trichloroethylene (TCE), the metallic element cobalt, and cobalt compounds...
Distress Screening in Oncology Leads to Better Doctor-Patient Relationships and Improved Outcomes
As many as 60% of patients with cancer report distress following a cancer diagnosis, and this stress can have a significant impact on patients’ well-being, resulting in psychosocial problems, physical side effects, and dissatisfaction with their health care. To examine the impact of distress ...
Introduction
As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...
Expert Point of View: Jean-Charles Soria, MD, PhD
Formal discussant Jean-Charles Soria, MD, PhD, of Institut Gustave Roussy, Villejuif, France, and Editor-in-Chief of Annals of Oncology (the official journal of the European Society for Medical Oncology [ESMO]), tried to put these findings into perspective. He pointed out that when applying the...
Pembrolizumab Plus Chemotherapy Improves Outcomes Over Chemotherapy Alone in Advanced NSCLC
Combining immunotherapy with a standard chemotherapy doublet appears to be an attractive option for the front-line treatment of advanced nonsquamous non–small cell lung cancer (NSCLC), according to the results of a phase II study presented at the 2016 European Society for Medical Oncology (ESMO)...
Expert Point of View: Axel Bex, MD, PhD
The formal discussant of this trial, Axel Bex, MD, PhD, of The Netherlands Cancer Institute in Amsterdam, was cautious in interpreting these results to be practice-changing. “I congratulate the investigators for the first-ever positive trial for adjuvant treatment of renal cell carcinoma,” he...
New Data Suggest Changes Needed to Guidelines for Determining Prognosis in Patients With Thyroid Cancer
A study from the Duke Cancer Institute (DCI) has found a lack of statistical evidence to support the current practice of treating thyroid cancer patients under age 45 differently from those 45 and older. The study, published recently by Adam et al in the Journal of Clinical Oncology,...
How ASCO Is Preparing Members for MACRA
On October 14, 2016, the Centers for Medicare & Medicaid Services (CMS) announced its final policy on what physicians need to do to begin implementing the Quality Payment Program outlined in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The Quality Payment Program is a...
Expert Point of View: Corey J. Langer, MD
Corey J. Langer, MD, Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, discussed the OAK study with The ASCO Post. Robust Data “In some ways, the OAK data are some of the most robust we have seen in the second-line setting. For ...
Personalized Risk Assessment Tool for Lung Cancer in Never, Light, and Heavy Smokers
Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light, and heavy smokers using a large Taiwanese prospective cohort study. By incorporating risk factor—in addition to...
Notable Gains in Survival Achieved With Atezolizumab in Non–Small Cell Lung Cancer
The programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) significantly improved overall survival, compared to docetaxel, in previously treated, advanced non–small cell lung cancer (NSCLC), according to preliminary results of the phase III OAK study. The findings are the first...
Study Raises Concerns About Timely Follow-up to Positive Mammogram for the Uninsured
A study by University of North Carolina (UNC) Lineberger Comprehensive Cancer Center researchers has found that younger, uninsured women in North Carolina had higher odds of missing a 60-day window for getting follow-up after an abnormal mammogram, even though research underscores the importance of ...
Ribociclib Granted FDA Priority Review for First-Line Treatment of Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
On November 1, the U.S. Food and Drug Administration (FDA) accepted a New Drug Application (NDA) for filing and granted Priority Review for ribociclib (LEE011) as first-line treatment of postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2...
French Trial Shows Addition of Androgen Maintenance Improves Survival in Elderly Patients With Acute Myeloid Leukemia
The addition of norethandrolone as maintenance therapy improved survival in patients aged ≥ 60 years with acute myeloid leukemia (AML), according to a French phase III trial reported in the Journal of Clinical Oncology by Pigneux et al. In the open-label trial, 330 patients with de novo AML or...
Adulthood BMI Increases Leading to Obesity Seem to Be Linked to an Increased Risk of Fatal Prostate Cancer
In a study of data from men in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial reported in the Journal of the National Cancer Institute, Kelly et al found that body mass index (BMI) increases during adulthood that lead to obesity are associated with an increased risk of...
Phase III SOLO-2 Trial Shows Significant Progression-Free Survival Benefit From Olaparib Treatment in BRCA-Mutated Metastatic Ovarian Cancer
Positive results were announced on October 26, 2016, from the phase III SOLO-2 trial, designed to determine the efficacy of olaparib (Lynparza) tablets (300 mg twice daily) as a monotherapy for the maintenance treatment of platinum-sensitive, BRCA-mutated relapsed ovarian cancer. Results from the...
Effect of Patient Age on Outcomes in Breast Reconstruction
The most comprehensive study of its kind to date found that older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women, without a significant increase in the risk for complications. As with patients across all age groups, the benefits of...
Japanese Trial Finds High Levels of Estrogen in Lung Tissue May Be Related to Synchronous Multiple Lung Adenocarcinoma in Postmenopausal Women
Thanks to advances in medical imaging, the detection rate for synchronous multiple lung adenocarcinoma has been on the rise. Cases of synchronous multiple lung adenocarcinoma in Japanese women have been on the rise, despite having a national smoking rate of less than 10% in recent years. This...
Poorer Outcomes Reported After ASCT in Double-Hit and Double-Expressor Relapsed and Refractory Lymphomas
Patients with double-hit and double-expressor relapsed/refractory diffuse large B-cell lymphomas have poorer outcomes after autologous stem cell transplantation (ASCT), according to the findings of a retrospective analysis reported by Herrera et al in the Journal of Clinical Oncology. Double-hit...
Genetic Testing May Be Beneficial in Identifying Patients With Breast Cancer at High Risk for Venous Thromboembolism
Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not ...
Potential Link Between Androgen-Deprivation Therapy for Prostate Cancer and Risk for Dementia
In a single-center analysis reported in JAMA Oncology, Nead et al found that the use of androgen-deprivation therapy for prostate cancer was associated with an increased risk for dementia. The study involved electronic medical record data from the Stanford University Health System from 1994 to...
Sexual Pain Experienced by Women After Cancer Is Common and May Be Ignored
Painful sex in women after cancer treatment is relatively common, often treatable, and needs to be addressed by medical providers, a University of California (UC), Davis, oncologist and researcher suggests. Vanessa Kennedy, MD, a gynecologic oncologist at UC Davis Health System, said that with...
Proportion of Cancer Deaths From Smoking Varies Across States and Is Highest in the South
Although smoking prevalence in the U.S. has declined by more than half since 1965, nearly 40 million adults still smoke cigarettes, resulting in about 167,133 cancer deaths in 2014, according to a study by the American Cancer Society. The study investigated cancer deaths among adults 35 and older...
Prolonged Length of Stays, Readmissions, and Discharge to Care Facilities Among Postoperative Patients With Advanced Cancer
Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities, and death, University of California (UC) Davis researchers have found. Their study, published by Bateni et al in PLOS One,...
Presence of Oral Bacterium in Esophageal Cancer Samples Associated With Shorter Patient Survival
Among Japanese patients with esophageal cancer, those whose cancer tested positive for DNA from the bacterium Fusobacterium nucleatum had shorter cancer-specific survival compared with those whose cancer had no DNA from the bacterium, according to study results published by Yamamura et al in...
24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer
In a matched retrospective analysis reported in The Lancet Oncology, Zhao et al identified and validated a 24-gene predictor of response to postoperative radiotherapy in prostate cancer. The analysis involved data from patients from five published U.S. studies (cohort, case-cohort, and...
Is Regorafenib Active in Advanced Nonadipocytic Soft-Tissue Sarcoma?
Mir et al found that regorafenib (Stivarga) was active in patients with advanced nonadipocytic soft-tissue sarcoma previously treated with an anthracycline, according to a French-Austrian phase II trial reported in The Lancet Oncology. Regorafenib should be evaluated further in this setting, the...
New Blood Test for Colorectal Cancer Recurrence Is Twice as Sensitive as CEA Test
In a new report published by Young et al in Cancer Medicine, a two-gene circulating tumor DNA (ctDNA) blood test for postsurgical monitoring of colorectal cancer (CRC) recurrence has been shown to detect twice the number of recurrence cases as carcinoembryonic antigen (CEA) testing, a standard of...
FDA Approves Pembrolizumab as First-Line Treatment for PD-L1–Positive Non–Small Cell Lung Cancer
On October 24, 2016, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express programmed cell death ligand 1 (PD-L1) as determined by an FDA-approved test. This is the...
Osimertinib Shows Activity in Pretreated EGFR Thr790Met–Positive Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Goss et al found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small cell lung cancer (NSCLC). Osimertinib is an EGFR tyrosine kinase...
CDC Recommends Only Two HPV Shots for Younger Adolescents
The Centers for Disease Control and Prevention (CDC) have recommended that 11- to 12-year-olds receive 2 doses of human papillomavirus (HPV) vaccine at least 6 months apart rather than the previously recommended 3 doses to protect against cancers caused by HPV infections. Teens and young adults who ...
Evaluating the FDA’s Approach to Cancer Clinical Trials
Since the announcement of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) on June 29, 2016, as part of the White House’s Cancer Moonshot, we’ve been working to further the FDA’s efforts to get new oncology products into the hands of patients. We are committed to...
Minimal Residual Disease Assessment and Prediction of Outcome in CLL Responders
Assessment of minimal residual disease was associated with improved prediction of outcome in responders, as well as complete responders, in patients with chronic lymphocytic leukemia (CLL) who respond to treatment. Kovacs et al reported these findings, which are based on an analysis of two phase...
Venetoclax Monotherapy Safe and Clinically Active in Acute Myelogenous Leukemia
A phase II study has found venetoclax (Venclexta) to be clinically active in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or those unfit for intensive chemotherapy, with an overall response rate of 19% and a tolerable safety profile. The study results, which were...
Key Guideline Recommendations
Human papillomavirus (HPV) DNA testing is recommended in all resource settings; visual inspection with acetic acid (VIA) may be used in the basic setting as a “stepping stone” that helps build health service capacity until HPV testing becomes available. Although cotesting with HPV and Papanicolaou...
ASCO Issues Global Recommendations to Increase Cervical Cancer Screening
Earlier this month, ASCO issued a new global guideline on screening for cervical cancer.1 The guideline provides evidence-based recommendations for screening, follow-up of positive screening results, and treatment of women with cervical precancers in countries worldwide. ASCO’s guideline...
My Catch-22 Predicament
In the spring of 2011, I was feeling so fatigued I needed to rest after walking just a few steps to the kitchen and not doing anything more strenuous than making a cup of coffee. Fortunately, I have a wonderful primary care physician who takes me seriously when I have a complaint about my health,...
Study Finds African American Cancer Survivors More Likely to Experience Lasting Debt Related to Cancer and Its Treatment
African American cancer survivors are more likely than whites to experience lasting debt or forgo necessary medical care as they struggle with the financial burden of cancer, whereas white cancer survivors are somewhat more likely to use existing assets to pay for their cancer care, according to a...
Affordable Care Act Increased Access to Cancer Care and Clinical Trial Participation Among Hispanics in California
Implementation of the Affordable Care Act may have led to a significant increase in the number of Hispanic breast cancer patients treated in California at a National Cancer Institute (NCI)-designated cancer center. Further, there was also an increase reported in the number of Hispanic women who...
Face Mask for Radiation Therapy
By the 1930s, the dangers of radiation were well known. American Martyr’s to Science Through the Roentgen Rays, published in 1936, documented the dead heroes of American radiology, from Clarence Daly, Thomas Edison’s associate, to Elizabeth Fleischman, the only woman in the group, who was a U.S....
Clinical Trials Actively Recruiting Patients With Metastatic Breast Cancer
Pilot Study Title: Pilot Study of 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole-Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain Study Type: Pilot/interventional/parallel assignment Study Sponsor ...
Lombardi’s Ruesch Center Policy Briefing Features Strategies to Reduce Costs
Two major developments in oncology—the dramatic success of some immunotherapies and targeted drugs and an equally dramatic rise in the cost of care—have created policy issues, more serious than ever, regarding access to care. It is a time “of extraordinary opportunities combined with inequities in ...
A Cancer Diagnosis Brings Two Sisters Back Together
Elizabeth Lesser is an award-winning writer and co-founder of the Omega Institute, the largest adult education center in the United States focusing on health, wellness, spirituality, and creativity. She is the author of several acclaimed books including Broken Open: How Difficult Times Can Help...
